Trinitrophenol

Trinitrophenol

SCHEMBL653352

O=[N+]([O-])c1cc([N+](=O)[O-])c([O-])c([N+](=O)[O-])c1.O=[N+]([O-])c1cc([N+](=O)[O-])c([O-])c([N+](=O)[O-])c1.[Zn+2]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TRPA1TRPV4

The experimentally established mechanism targets of Trinitrophenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
GPR35 Q9HC97 5/20 0.55
TDP1 Q9NUW8 3/20 0.54
HPGD P15428 2/20 0.54
MAPK1 P28482 2/20 0.54
HIF1A Q16665 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
TTR P02766 1/20 0.54
CYP1A2 P05177 1/20 0.54
MAPT P10636 1/20 0.54
CYP2C9 P11712 1/20 0.54
ALOX15 P16050 1/20 0.54
ALOX12 P18054 1/20 0.54
RECQL P46063 1/20 0.54
PMP22 Q01453 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CYP3A4 P08684 1/20 0.52
CYP19A1 P11511 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trinitrophenol SCHEMBL1503374 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL7161635 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL1132384 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL597737 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL2218621 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL11746242 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL11029128 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL2197455 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL48278 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1
Trinitrophenol SCHEMBL5908862 0.95 ALDH1A1 (0.55) ALDH1A1GPR35TDP1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2182947-B1 COMPOSITIONS WITH ENHANCED BIOAVAILABILITY AND FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION UNIV YALE (US) 2019-09-04 EP claimed
CN-105252622-A Method for manufacturing craft through waste bamboo ANHUI LIAOYUAN TRADE CO LTD 2016-01-20 CN claimed
WO-2015153552-A1 FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION WITH ENHANCED ACTIVITY YALE UNIVERSITY (US) 2015-10-08 WO claimed
US-20150231175-A1 COMPOSITIONS WITH ENHANCED BIOAVAILABILITY AND FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION UNIV YALE (US) 2015-08-20 US claimed
US-20140154339-A1 Fast Acting Inhibitor of Gastric Acid Secretion YALE UNIVERSITY 2014-06-05 US claimed
CN-102014939-A Homeopathic formulations DEVICHAND OSWAL GUNVANT 2011-04-13 CN claimed
US-20100150861-A1 COMPOSTIONS WITH ENHANCED BIOAVAILABILITY AND FAST ACTING INHIBITOR OR GASTRIC ACID SECRETION YALE UNIVERSITY (US) 2010-06-17 US claimed
EP-2182947-A2 COMPOSITIONS WITH ENHANCED BIOAVAILABILITY AND FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION YALE UNIVERSITY (US) 2010-05-12 EP claimed
WO-2009017624-A2 COMPOSITIONS WITH ENHANCED BIOAVAILABILITY AND FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION YALE UNIVERSITY (US) 2009-02-05 WO claimed
US-20080038368-A1 Fast acting inhibitor of gastric acid secretion YALE UNIVERSITY (US) 2008-02-14 US claimed
EP-0589047-B1 METHOD OF TREATING INFECTIOUS DISEASE, METHOD OF PREVENTING PUTREFACTION OF COSMETIC, AND ANTIBACTERIAL/ANTIFUNGAL AGENT AND COSMETIC OTSUKA PHARMA CO LTD (JP) 1999-06-09 EP claimed
CN-1144599-A Treatment method and liquid for withered green plant recovering its active state ZHANG CHENGZHI (CN) 1997-03-12 CN claimed
EP-0589047-A1 METHOD OF TREATING INFECTIOUS DISEASE, METHOD OF PREVENTING PUTREFACTION OF COSMETIC, AND ANTIBACTERIAL/ANTIFUNGAL AGENT AND COSMETIC OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-03-30 EP claimed
US-4455150-A Chemically enhanced combustion of water-slurry fuels OLEN KENNETH R 1984-06-19 US claimed
US-12570541-B1 Multiphase nanocomposite material production IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2026-03-10 US disclosed
US-12508569-B1 Multiphase nanocomposite material IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2025-12-30 US disclosed
US-12421125-B1 Particulate nanocomposite material IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2025-09-23 US disclosed
US-4455150-A Chemically enhanced combustion of water-slurry fuels OLEN KENNETH R 1984-06-19 US disclosed
US-4125474-A Process for producing ferrogmagnetic iron oxide powder comprising a pre-treatment with a reducing agent FUJI PHOTO FILM CO., LTD. (JP) 1978-11-14 US disclosed
US-4069164-A COBALT-CONTAINING IRON OXIDE, OXIDIZER FUJI PHOTO FILM CO., LTD. (JA) 1978-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570541-B1 Multiphase nanocomposite material production ZKSCAN2, ZRANB2, FTH1 ALDH1A1 4038/4885GPR35 4466/4885TDP1 4872/4885
US-12508569-B1 Multiphase nanocomposite material ZKSCAN2, OCIAD2, ZRANB2 ALDH1A1 4810/4885GPR35 4792/4885TDP1 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.